Marta Gonzalez appointed co-head of Eversheds Sutherland’s global Healthcare Group

Eversheds Sutherland has appointed Spanish office partner Marta González as co-head of Eversheds-Sutherland’s International Health Sciences Group.

Jacobo Martinez, managing partner of Eversheds Sutherland in Spain, maintains that “Marta Gonzalez will bring a renewed and strategic vision to the team, both from her international position and from her position as head of the Committee in Spain.” “We are confident that her leadership will strengthen our position in the market,” she adds.

Marta González

A partner in the firm’s Litigation and Health Sciences Department in the Madrid office and head of the Pharma Unit, González has extensive experience in advising companies in the pharmaceutical and healthcare sector, particularly in litigation arising from patent infringement, defective drugs and unfair competition.

Prior to joining Eversheds Sutherland, she worked as in-house counsel for the pharmaceutical companies Glaxosmithkline (Spain) and Celgene International Sarl (Switzerland), so her experience in pharmaceutical litigation (product liability and patents) added to her in-house work in commercial and regulatory matters, gives her a remarkable experience and expertise in the sector.

She will be joined by Elizabeth Graves, a partner in Eversheds Sutherland’s UK Labor and Employment practice, as head of the International Health Group. Graves has a strong background in managing the employment aspects of cross-border M&A transactions and complex litigation. His work spans multiple sectors, including health sciences, financial services and technology.

New Head of Healthcare Steering Committee

González has also been appointed as the new head of Eversheds Sutherland Spain’s Healthcare Steering Committee, effective January 1, 2025. This appointment reflects the firm’s commitment to growth and innovation in the healthcare sector in the Spanish office of the firm.

“Our goal is to provide quality solutions to our clients at a time when the industry is facing an increasingly complex regulatory environment,” says Marta González.